We suggest that combining EGFR-TKI at the early stage of radiotherapy might not only produce a longer-term effect that is beneficial to the enhancement of the radiotherapy outcome but also inhibit tumor recurrence due to radiation-induced stemness-responsive cells. Here, EGFR is linked to neoplasm.